Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Net Cash Flow (2016 - 2025)

Arcadia Biosciences (RKDA) has disclosed Net Cash Flow for 12 consecutive years, with -$256000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Net Cash Flow rose 83.67% year-over-year to -$256000.0, compared with a TTM value of -$2.8 million through Sep 2025, up 58.22%, and an annual FY2024 reading of -$2.2 million, up 84.08% over the prior year.
  • Net Cash Flow was -$256000.0 for Q3 2025 at Arcadia Biosciences, up from -$1.8 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $16.8 million in Q1 2021 and bottomed at -$9.5 million in Q2 2023.
  • Average Net Cash Flow over 5 years is -$785789.5, with a median of -$1.8 million recorded in 2025.
  • The sharpest move saw Net Cash Flow surged 268.85% in 2021, then plummeted 293.47% in 2023.
  • Year by year, Net Cash Flow stood at -$6.9 million in 2021, then surged by 69.82% to -$2.1 million in 2022, then plummeted by 97.25% to -$4.1 million in 2023, then skyrocketed by 108.14% to $333000.0 in 2024, then crashed by 176.88% to -$256000.0 in 2025.
  • Business Quant data shows Net Cash Flow for RKDA at -$256000.0 in Q3 2025, -$1.8 million in Q2 2025, and -$1.1 million in Q1 2025.